Optimisation of UCB's Transient Expression Platforms

After graduation from the Aachen University of Applied Sciences in Germany I worked for a number of years as a Process Development Scientist at AstraZeneca in Sweden in cell line generation and developing scalable fermentation processes for mammalian cell cultures. After this I moved to the UK and joined the New Meds Division of UCB working within the transient gene expression group. Over my 10 years at UCB I have implemented many improvements to both our CHO and HEK293 transient expression platforms which have led to significant improvement in titre and throughput. I am now currently part of the alternative antibody format group helping to design and improve expression of 'difficult to express proteins'.